Last reviewed · How we verify
Methylglyoxal Bis(Guanylhydrazone) (MITOGUAZONE)
Mitoguazone works by inhibiting the enzyme ribonucleotide reductase, which is involved in DNA synthesis and repair.
Methylglyoxal Bis(Guanylhydrazone), also known as mitoguazone, is a small molecule drug in the mitoguazone class. Its exact target is unknown, but it is used to treat certain types of cancer. The commercial status of mitoguazone is unclear, and it may be patented or available as a generic medication. Key safety considerations include potential side effects and interactions with other medications. Further research is needed to fully understand the pharmacology and clinical use of mitoguazone.
At a glance
| Generic name | MITOGUAZONE |
|---|---|
| Drug class | mitoguazone |
| Target | Amiloride-sensitive amine oxidase [copper-containing], S-adenosylmethionine decarboxylase proenzyme |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Mechanism of action
Think of mitoguazone like a brake on a car. The brake (mitoguazone) slows down the car (DNA synthesis and repair) by blocking the accelerator (ribonucleotide reductase). This can help prevent cancer cells from growing and dividing.
Approved indications
Common side effects
Key clinical trials
- Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (PHASE1,PHASE2)
- Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma (PHASE2)
- Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors (PHASE1,PHASE2)
- Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma (PHASE1,PHASE2)
- INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study (PHASE2)
- Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma (PHASE2)
- Engaging Immigrants in Preventive Parenting Interventions (NA)
- Integrating Geriatric Assessment for Older Patients Diagnosed With Acute Myelogenous Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylglyoxal Bis(Guanylhydrazone) CI brief — competitive landscape report
- Methylglyoxal Bis(Guanylhydrazone) updates RSS · CI watch RSS